Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 781-790

  von Moos, Roger ^a   Thuerlimann, Beat J K ^b   Aapro, Matti ^c   Rayson, Daniel ^d   Harrold, Karen ^e   Sehouli, Jalid ^f   Scotte, Florian ^g   Lorusso, Domenica ^h   Dummer, Reinhard ⁱ   Lacouture, Mario E ^j   Lademann, Jürgen ^f   Hauschild, Axel ^k  

^a Medical Oncology   (Switzerland)

^b Senology Center of Eastern Switzerland   (Switzerland)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Hand foot syndrome; Palmar plantar erythrodysesthesia; Pegylated liposomal doxorubicin; Recommendations

Indexed keywords

AMIFOSTINE; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOXORUBICIN; PYRIDOXINE;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG INFORMATION; EARLY DIAGNOSIS; HAND FOOT SYNDROME; HEALTH PROMOTION; HUMAN; INFORMATION RETRIEVAL; KAPOSI SARCOMA; MEDICAL EXPERT; MEDICAL INFORMATION; MEDLINE; NONHUMAN; OVARY CANCER; PATHOGENESIS; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE;

ADRENAL CORTEX HORMONES; DERMATOLOGIC AGENTS; DOXORUBICIN; DRUG ERUPTIONS; ERYTHEMA; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; HYPOTHERMIA, INDUCED; NEOPLASMS; PATIENT EDUCATION AS TOPIC; POLYETHYLENE GLYCOLS; PYRIDOXINE; QUALITY OF LIFE; RISK FACTORS; SYNDROME;

EID: 41949089700     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.01.028     Document Type: Article

References (70)

1. Zuehlke R.L. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 148 (1974) 90-92
2. Kampmann K.K., Graves T., and Rogers S.D. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 63 (1989) 2482-2485
3. Noble J.P., Boisnic S., Branchet-Gumila M.C., and Poisson M. Palmar erythema: cutaneous marker of neoplasms. Dermatology 204 (2002) 209-213
4. Nielsen M. Painful palmar-plantar erythema in myeloproliferative disease. Arch Dermatol 121 (1985) 1240
5. Crider M.K., Jansen J., Norins A.L., and McHale M.S. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 122 (1986) 1023-1027
6. Troussard X., Dompmartin A., and Dechaufour F. Acral erythema and acute GVHD. Bone Marrow Transplant 11 (1993) 501
7. Hui Y.F., Giles F.J., and Cortes J.E. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome-recall following different chemotherapy agents. Invest New Drugs 20 (2002) 49-53
8. Marina N.M., Cochrane D., Harney E., Zomorodi K., Blaney S., Winick N., et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 8 (2002) 413-418
9. Caeylx (pegylated liposomal doxorubicin). Product information, Schering-Plough Corporation; 2006.
10. Abeloff M.D., Armitage J.O., Niederhuber J.E., et al. Clinical oncology. 3rd ed. (2004), Churchill Livingstone, Philadelphia (PA)
11. Baack B.R., and Burgdorf W.H. Chemotherapy-induced acral erythema. J Am Acad Dermatol 24 (1991) 457-461
12. Narasimhan P., Narasimhan S., Hitti I.F., and Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 73 (2004) 101-106
13. Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89 (2000) 1037-1047
14. Stubblefield M.D., Custodio C.M., Kaufmann P., et al. Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report. J Clin Neuromuscul Dis 7 (2006) 128-132
15. Prussick R. Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy. Semin Cutan Med Surg 15 (1996) 267-276
16. Heo Y.S., Chang H.M., Kim T.W., et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44 (2004) 1166-1172
17. Lotem M., Hubert A., Lyass O., et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136 (2000) 1475-1480
18. DCTD, NCI, NIH, et al: Common terminology criteria for adverse events v3.0 2003 (CTCAE). [accessed July 2006].
19. Nagore E., Insa A., and Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1 (2000) 225-234
20. Doxil (doxorubicin HCL liposomal injection): product information. Raritan, NJ, Tibotec Therapeutics, Division of Ortho Biotech Products, LP; 2005.
21. Baer M.R., King L.E., and Wolff S.N. Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 102 (1985) 556
22. Levine L.E., Medenica M.M., Lorincz A.L., Soltani K., Raab B., and Ma A. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 121 (1985) 102-104
23. Payne A.S., James W.D., and Weiss R.B. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 33 (2006) 86-97
24. Gordon K.B., Tajuddin A., Guitart J., Kuzel T.M., Eramo L.R., and VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75 (1995) 2169-2173
25. Gabizon A., Goren D., Horowitz A.T., et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24 (1997) 337-344
26. Charrois G.J., and Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 1663 (2004) 167-177
27. Charrois G.J., and Allen T.M. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609 (2003) 102-108
28. Jacobi U., Waibler E., Schulze P., et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann Oncol 16 (2005) 1210-1211
29. Lademann J., Martschick A., Jacobi U., et al. Investigation of doxorubicin on the skin: a spectroscopic study to understand the pathogenesis of PPE. Proc Am Soc Clin Oncol 23 No. 16S, Part I or II (2005) 5093 [abstract]
30. Gordinier M.E., Dizon D.S., Fleming E.L., et al. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecol Oncol 103 (2006) 72-74
31. Amantea M., Newman M.S., Sullivan T.M., Forrest A., and Working P.K. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18 (1999) 17-26
32. Coleman R.E., Biganzoli L., Canney P., et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42 (2006) 882-887
33. 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70 (2006) 141-146
34. Sehouli J., Oskay-Ozcelik G., Kuhne J., et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 17 (2006) 957-961
35. Lorusso D., Naldini A., Testa A., D'Agostino G., Scambia G., and Ferrandina G. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?. Oncology 67 (2004) 243-249
36. Gordon A.N., Granai C.O., Rose P., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18 (2000) 3098-3100
37. Muggia F., Hainsworth J., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
38. 2) in the treatment of gynecologic cancers. Gynecol Oncol 97 (2005) 374-378
39. Rose P.G., Maxson J.H., Fusco N., Mossbruger K., and Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82 (2001) 323-328
40. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10 (2005) 205-214
41. Stewart S., Jablonowski H., Goebel F.D., et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 16 (1998) 683-691
42. Martin-Carbonero L., Barrios A., Saballs P., et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18 (2004) 1737-1739
43. Gilbar P. Palmar-plantar erythrodysesthesia. J Clin Pharmacy Pract 9 (2003) 137-150
44. Yee S. Prevention and management of doxil-related side effects: basic strategies. Proc Am Soc Clin Oncol 17 (1998) 281 [abstract]
45. Cancer Care Ontario - Professional Pharmacy Advisory Committee - Medication Information Sheets Working Group. Patient info sheet: hand-foot syndrome; 2004.
46. Pike K. Hand-foot syndrome. Oncol Nurs Forum 28 (2001) 1519-1520
47. Wilkes G.M., and Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 9 (2005) 103-106
48. Gerbrecht B.M. Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 26 (2003) 161-167
49. Grenier N., Lebel V., Gill M., et al. Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC). Proc Am Soc Clin Oncol 23 No 16S, Part I of II (2005) 8198 [abstract]
50. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
51. Hau P., Fabel K., Baumgart U., et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100 (2004) 1199-1207
52. Lee S., Lee S., Chun Y., et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. Proc Am Soc Clin Oncol 25 (2007) 9007 [abstract]
53. Webster-Gandy J.D., How C., and Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11 (2007) 238-246
54. Vail D.M., Chun R., Thamm D.H., et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4 (1998) 1567-1571
55. Molpus K.L., Anderson L.B., Craig C.L., and Puleo J.G. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93 (2004) 513-516
56. Sayer R.A., Apte S., and Tedjarati S.S. Regional cooling significantly reduces liposomal doxorubicin-induced palmar-plantar erythrodysesthesias (PPE) in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 24 18S (2006) 18507 [abstract]
57. Drake R.D., Lin W.M., King M., Farrar D., Miller D.S., and Coleman R.L. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94 (2004) 320-324
58. Colemen R.L., Lin W.M., Miller D.S., et al. Oral dexamethasone (DMS) attenuates doxil-induced palmar plantar erythema (PPE) in patients with recurrent gynecologic malignancies. Proc Am Soc Clin Oncol 20 (2001) 883 [abstract]
59. Lopez A.M., Wallace L., Dorr R.T., Koff M., Hersh E.M., and Alberts D.S. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44 (1999) 303-306
60. Ferguson J. Dimethyl sulfoxide (DMSO), Material Safety Data Sheet (MSDS GCC1-7); 2004.
61. Vogin E.E., Carson S., Cannon G., Linegar C.R., and Rubin L.F. Chronic toxicity of DMSO in primates. Toxicol Appl Pharmacol 16 (1970) 606-612
62. Smith E.R., Hadidian Z., and Mason M.M. The toxicity of single and repeated dermal applications of dimethyl sulfoxide. J Clin Pharmacol J New Drugs 8 (1968) 315-321
63. Wood D.C., Wirth N.V., Weber F.S., and Palmquist M.A. Mechanism considerations of dimethyl sulfoxide (DMSO)-lenticular changes in rabbits. J Pharmacol Exp Ther 177 (1971) 528-535
64. Jajeh A., Agbemadzo B., Zalzaleh G., et al. Amifostine in the prevention of liposomal doxorubicin induced palmar-plantar erythrodysesthesia (PPE). Blood 100 (2002) 5115 [abstract]
65. Colbern G., Steinmetz K., Musterer R., et al. Amifostine reduces severity and incidence of Doxil-associated palmar/plantar erythrodysesthesia in rats but does not reduce Doxil antitumor efficacy or alter pharmacokinetics in mice. Proc Am Soc Clin Oncol 19 (2000) 815 [abstract]
66. Herrling Th, Zastrow L, Groth N, SÖFW, 124 Jhrg 5/98, Classification of cosmetic products - the Radical Protection Factor (RPF). p. 282-4.
67. Lademann J, Martschick A, Sehouli H, et al. Treatment of the PPE. In: Proceedings of the second Berlin symposium on quality of life. Berlin; 2006.
68. Brown S.O., Calhoun E., and Bennett C.L. Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodysesthesia (PPE) among women with metastatic breast cancer. Proc Am Soc Clin Oncol 23 No. 16S, Part I of II (2005) 788 [abstract]
69. Hackbarth M, Haas N, Lichtenegger W, et al. Skin side effects of systemic chemotherapy and their impact on HQOL in patients with gynecologic malignomas: a prospective prevalence study. In: Proceedings of the second Berlin symposium on quality of life. Berlin; 2006.
70. Ener R.A., Meglathery S.B., and Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 15 (2004) 858-862